Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Puma Biotech (PBYI) Surges Following Results; Analyst Sees Few Excuses Not to Own
March 1, 2019 10:51 AM ESTPuma Biotech (NASDAQ: PBYI) pushes to highs following earnings after the close. Shares are up 42% on volume that is running 24x the norm.
Citi analyst Yigal Nochomovitz said with the launch back on track, they see few excuses left not to own... More
Puma Biotechnology (PBYI) PT Raised to $37 at RBC Capital
March 1, 2019 6:51 AM ESTRBC Capital analyst Kennen MacKay raised the price target on Puma Biotechnology (NASDAQ: PBYI) to $37.00 (from $29.00) while maintaining a Sector Perform rating following results.
MacKay called results "unexpectedly impressive" with +16% q/q growth versus a tepid +4% in Q3.
"Inventory confounds the... More
Puma Biotech (PBYI) Misses Q4 EPS by 3c
February 28, 2019 4:11 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.80), $0.03 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $71.1 million versus the consensus estimate of $53.65 million.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
... More